Quinoxalinedione nmda receptor antagonists
CA 2199845 C · Owner: Carr, Christopher Lee · Inventors: Carr, Christopher Lee; Mowbray, Charles Eric; Stobie, Alan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I), (see formula I) wherein R1 and R2 are each independently C1 Br, CH3, CH2CH3, or CF3; R3 is H, CH3 or CH2CH3; and X is a 5-membered heteroaromatic group containing up to four nitrogen atoms attached via a nitrogen atom, the said group being optionally substituted by C1-C6 alkyl or (CH2)nNR4R5 wherein n is an, integer from 1 to 5 and R4 and R5 are each independently H C1-C6 alkyl, C3-C6 cycloalkyl or C1-C4 alkyl substituted by phenyl or pyridyl, or R4 and R5 are linked to form together, with the nitrogen atom to which they are attached a, pyrrolidine, piperidine, piperazine N-(C1-C4 alkyl), piperazine, morpholine or azepine group or when X is triazolyl, said group …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 1, 1995 and granted August 1, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 1, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 1, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.